EA038965B1 - Частицы пористого углерода для применения при лечении или профилактике заболевания печени - Google Patents
Частицы пористого углерода для применения при лечении или профилактике заболевания печени Download PDFInfo
- Publication number
- EA038965B1 EA038965B1 EA201491690A EA201491690A EA038965B1 EA 038965 B1 EA038965 B1 EA 038965B1 EA 201491690 A EA201491690 A EA 201491690A EA 201491690 A EA201491690 A EA 201491690A EA 038965 B1 EA038965 B1 EA 038965B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- particles
- liver
- pore volume
- porous carbon
- pores
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B32/00—Carbon; Compounds thereof
- C01B32/15—Nano-sized carbon materials
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/16—Pore diameter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1204696.7A GB201204696D0 (en) | 2012-03-16 | 2012-03-16 | Therapy |
| PCT/GB2013/050673 WO2013136094A1 (en) | 2012-03-16 | 2013-03-15 | Porous carbon particles for use in the treatment or prevention of liver disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491690A1 EA201491690A1 (ru) | 2015-02-27 |
| EA038965B1 true EA038965B1 (ru) | 2021-11-16 |
Family
ID=46052080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491690A EA038965B1 (ru) | 2012-03-16 | 2013-03-15 | Частицы пористого углерода для применения при лечении или профилактике заболевания печени |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9844568B2 (enExample) |
| EP (2) | EP2825181B1 (enExample) |
| JP (2) | JP6293680B2 (enExample) |
| KR (2) | KR102441934B1 (enExample) |
| CN (1) | CN104363916B (enExample) |
| AU (1) | AU2013234099B2 (enExample) |
| BR (1) | BR112014022810B1 (enExample) |
| DK (1) | DK2825181T3 (enExample) |
| EA (1) | EA038965B1 (enExample) |
| GB (1) | GB201204696D0 (enExample) |
| IN (1) | IN2014DN07637A (enExample) |
| MY (1) | MY169093A (enExample) |
| NZ (1) | NZ631429A (enExample) |
| SG (1) | SG11201405771QA (enExample) |
| WO (1) | WO2013136094A1 (enExample) |
| ZA (1) | ZA201406989B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
| ES2727153T3 (es) * | 2014-04-17 | 2019-10-14 | Immutrix Therapeutics Inc | Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas |
| TWI607765B (zh) * | 2014-08-27 | 2017-12-11 | Kureha Corp | Adsorbents for oral administration, and nephropathy therapeutic agents and liver disease therapeutic agents |
| KR102328323B1 (ko) | 2017-03-31 | 2021-11-19 | 엑시얼 테라퓨틱스, 인크. | 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제 |
| EP3476818A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved carbon source |
| EP3476817A1 (en) | 2017-10-27 | 2019-05-01 | Heraeus Battery Technology GmbH | A process for the preparation of a porous carbon material using an improved amphiphilic species |
| WO2019131209A1 (ja) * | 2017-12-27 | 2019-07-04 | 株式会社クラレ | 活性炭およびその製法 |
| JP7228498B2 (ja) * | 2018-10-24 | 2023-02-24 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
| WO2020085282A1 (ja) * | 2018-10-24 | 2020-04-30 | フタムラ化学株式会社 | フェノール樹脂の製造方法 |
| JP7338993B2 (ja) * | 2019-03-06 | 2023-09-05 | 株式会社クラレ | 多孔質炭素および多孔質炭素の製造方法 |
| JP7061640B2 (ja) * | 2019-04-16 | 2022-04-28 | フタムラ化学株式会社 | 活性炭吸着剤の製造方法 |
| WO2020213559A1 (ja) * | 2019-04-16 | 2020-10-22 | フタムラ化学株式会社 | 活性炭吸着剤の製造方法 |
| JP7563145B2 (ja) * | 2019-12-05 | 2024-10-08 | ａｒｔｉｅｎｃｅ株式会社 | 多孔質炭素及びその製造方法 |
| WO2024261472A1 (en) * | 2023-06-20 | 2024-12-26 | Yaqrit Limited | Porous carbon particles for use in therapy |
| KR102971111B1 (ko) | 2023-09-05 | 2026-06-02 | 한국생산기술연구원 | 열경화성 에폭시 조성물, 이의 경화물 및 용도 |
| CN121925310A (zh) * | 2025-03-28 | 2026-04-24 | 大阪燃气化学有限公司 | 麻醉气体吸附剂、麻醉气体吸附过滤器、吸入麻醉系统以及麻醉气体的去除方法 |
| JP7724390B1 (ja) * | 2025-03-28 | 2025-08-15 | 大阪ガスケミカル株式会社 | 麻酔ガス吸着剤、麻酔ガス吸着剤の製造方法、麻酔ガス吸着フィルター、吸入麻酔システム、および、麻酔ガスの除去方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012380A2 (en) * | 2000-08-09 | 2002-02-14 | Materials And Separations Technology International Limited | Porous carbons |
| EP1525886A1 (en) * | 2003-10-22 | 2005-04-27 | Kureha Chemical Industry Co., Ltd. | Absorbent for oral administration, and agent for treating or preventing renal or liver disease |
| EP1745793A1 (en) * | 2004-04-02 | 2007-01-24 | Kureha Corporation | Adsorbent for oral administration, therapeutic or preventive agent for kidney disease, and therapeutic or preventive agent for liver disease |
| WO2011070363A1 (en) * | 2009-12-09 | 2011-06-16 | Mast Carbon International Ltd | Carbon and its use in blood cleansing applications |
| WO2012050025A1 (ja) * | 2010-10-12 | 2012-04-19 | フタムラ化学株式会社 | 医薬用吸着剤及びその製造方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5332637B2 (enExample) * | 1973-05-09 | 1978-09-09 | ||
| JPS51151693A (en) | 1975-06-23 | 1976-12-27 | Eisai Co Ltd | Coated bead-like activated carbon for blood purification |
| JPS5673542A (en) | 1979-11-22 | 1981-06-18 | Kureha Chem Ind Co Ltd | Adsorbent |
| JPS5731864A (en) * | 1980-08-04 | 1982-02-20 | Teijin Ltd | Oral activated carbon microcapsule |
| RU2177319C2 (ru) * | 1999-03-30 | 2001-12-27 | Российская медицинская академия последипломного образования МЗ РФ | Способ лечения гиперэндотоксинемии |
| JP3522708B2 (ja) | 2001-04-11 | 2004-04-26 | 呉羽化学工業株式会社 | 経口投与用吸着剤 |
| JP4311923B2 (ja) * | 2002-10-07 | 2009-08-12 | 株式会社クレハ | 経口投与用肝疾患治療又は予防剤 |
| EP1407772B9 (en) | 2002-10-09 | 2007-02-21 | Kureha Corporation | Pharmaceutical composition comprising porous spherical carbonaceous substance and its use for the treatment of renal and liver diseases |
| CA2504517C (en) | 2002-11-01 | 2008-08-12 | Kureha Corporation | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| US7651974B2 (en) | 2002-11-01 | 2010-01-26 | Kureha Chemical Industry Co., Ltd. | Adsorbent for oral administration |
| JP2005089306A (ja) * | 2003-09-12 | 2005-04-07 | Ajinomoto Co Inc | 炎症性腸疾患治療用の経直腸投与製剤 |
| JP4382629B2 (ja) * | 2003-10-22 | 2009-12-16 | 株式会社クレハ | 経口投与用吸着剤、並びに腎疾患治療又は予防剤、及び肝疾患治療又は予防剤 |
| TWI370012B (en) | 2004-04-02 | 2012-08-11 | Kureha Corp | Adsorbent for oral administration, and agent for treating or preventing renal or liver disease |
| JP2007045775A (ja) | 2005-08-11 | 2007-02-22 | Japan Organo Co Ltd | 含水活性炭及びその製造方法 |
| DE102005062160A1 (de) | 2005-12-19 | 2007-06-21 | BLüCHER GMBH | Aktivkohle für die medizinische Verwendung |
| US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| CA2660883C (en) | 2006-10-09 | 2014-12-09 | British American Tobacco (Investments) Limited | Carbonising and/or activating carbonaceous material |
| BRPI0719161A2 (pt) | 2006-10-09 | 2014-02-04 | British American Tobacco Co | Processos para produzir glóbulos sólidos discretos de material polimérico, para preparar um produto de carbono ativado, e para preparar um produto particulado carbonizado, aparelho para formar glóbulos sólidos discretos de material polimérico, métodos para carbonizar e ativar material carbonáceo, e para preparar carbono ativado, e, forno rotativo. |
| WO2010138519A2 (en) | 2009-05-27 | 2010-12-02 | Ocera Therapeutics, Inc. | Use of adsorbent carbon microspheres for the treatment of pruritus |
| PL2538930T3 (pl) | 2010-02-23 | 2016-11-30 | Preparaty do doustnego dostarczania środków adsorbujących do jelita | |
| GB201204696D0 (en) * | 2012-03-16 | 2012-05-02 | Ucl Business Plc | Therapy |
-
2012
- 2012-03-16 GB GBGB1204696.7A patent/GB201204696D0/en not_active Ceased
-
2013
- 2013-03-15 JP JP2014561519A patent/JP6293680B2/ja active Active
- 2013-03-15 DK DK13711116.7T patent/DK2825181T3/da active
- 2013-03-15 WO PCT/GB2013/050673 patent/WO2013136094A1/en not_active Ceased
- 2013-03-15 EP EP13711116.7A patent/EP2825181B1/en active Active
- 2013-03-15 BR BR112014022810-8A patent/BR112014022810B1/pt active IP Right Grant
- 2013-03-15 US US14/385,332 patent/US9844568B2/en active Active
- 2013-03-15 KR KR1020207022420A patent/KR102441934B1/ko active Active
- 2013-03-15 CN CN201380025257.6A patent/CN104363916B/zh active Active
- 2013-03-15 SG SG11201405771QA patent/SG11201405771QA/en unknown
- 2013-03-15 NZ NZ631429A patent/NZ631429A/en unknown
- 2013-03-15 IN IN7637DEN2014 patent/IN2014DN07637A/en unknown
- 2013-03-15 AU AU2013234099A patent/AU2013234099B2/en active Active
- 2013-03-15 MY MYPI2014002656A patent/MY169093A/en unknown
- 2013-03-15 EA EA201491690A patent/EA038965B1/ru unknown
- 2013-03-15 KR KR1020147029083A patent/KR102142504B1/ko active Active
- 2013-03-15 EP EP19211615.0A patent/EP3650031B1/en active Active
-
2014
- 2014-09-25 ZA ZA2014/06989A patent/ZA201406989B/en unknown
-
2018
- 2018-02-14 JP JP2018023609A patent/JP6647570B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002012380A2 (en) * | 2000-08-09 | 2002-02-14 | Materials And Separations Technology International Limited | Porous carbons |
| EP1525886A1 (en) * | 2003-10-22 | 2005-04-27 | Kureha Chemical Industry Co., Ltd. | Absorbent for oral administration, and agent for treating or preventing renal or liver disease |
| EP1745793A1 (en) * | 2004-04-02 | 2007-01-24 | Kureha Corporation | Adsorbent for oral administration, therapeutic or preventive agent for kidney disease, and therapeutic or preventive agent for liver disease |
| WO2011070363A1 (en) * | 2009-12-09 | 2011-06-16 | Mast Carbon International Ltd | Carbon and its use in blood cleansing applications |
| WO2012050025A1 (ja) * | 2010-10-12 | 2012-04-19 | フタムラ化学株式会社 | 医薬用吸着剤及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102441934B1 (ko) | 2022-09-08 |
| DK2825181T3 (da) | 2020-04-14 |
| IN2014DN07637A (enExample) | 2015-05-15 |
| EP2825181A1 (en) | 2015-01-21 |
| EP3650031B1 (en) | 2026-07-01 |
| MY169093A (en) | 2019-02-18 |
| EP2825181B1 (en) | 2020-01-08 |
| EA201491690A1 (ru) | 2015-02-27 |
| JP6647570B2 (ja) | 2020-02-14 |
| NZ631429A (en) | 2016-09-30 |
| AU2013234099B2 (en) | 2017-03-30 |
| SG11201405771QA (en) | 2014-10-30 |
| JP6293680B2 (ja) | 2018-03-14 |
| KR20200096991A (ko) | 2020-08-14 |
| KR102142504B1 (ko) | 2020-08-07 |
| BR112014022810B1 (pt) | 2021-04-13 |
| AU2013234099A1 (en) | 2014-10-02 |
| CN104363916B (zh) | 2018-09-25 |
| KR20150002675A (ko) | 2015-01-07 |
| WO2013136094A1 (en) | 2013-09-19 |
| CN104363916A (zh) | 2015-02-18 |
| ZA201406989B (en) | 2015-12-23 |
| EP3650031A1 (en) | 2020-05-13 |
| EP3650031C0 (en) | 2026-07-01 |
| US20150064256A1 (en) | 2015-03-05 |
| US9844568B2 (en) | 2017-12-19 |
| JP2015516373A (ja) | 2015-06-11 |
| JP2018111699A (ja) | 2018-07-19 |
| GB201204696D0 (en) | 2012-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6647570B2 (ja) | 肝疾患の治療及び予防における使用のための多孔性炭素粒子 | |
| Jabbari et al. | Evaluation of encapsulated eugenol by chitosan nanoparticles on the aggressive model of rheumatoid arthritis | |
| Zhong et al. | Microalgae‐based hydrogel for inflammatory bowel disease and its associated anxiety and depression | |
| Park et al. | Bioinspired DNase‐I‐coated melanin‐like nanospheres for modulation of infection‐associated NETosis dysregulation | |
| Zhang et al. | Prodrug integrated envelope on probiotics to enhance target therapy for ulcerative colitis | |
| Zhai et al. | Long-term exposure to polystyrene microspheres and high-fat diet–induced obesity in mice: evaluating a role for microbiota dysbiosis | |
| Lu et al. | Curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling | |
| Tan et al. | Peritoneal air exposure elicits an intestinal inflammation resulting in postoperative ileus | |
| Wang et al. | Protective effects of alginate–chitosan microspheres loaded with alkaloids from Coptis chinensis Franch. and Evodia rutaecarpa (Juss.) Benth.(Zuojin Pill) against ethanol-induced acute gastric mucosal injury in rats | |
| JP6978122B2 (ja) | 自閉症および関連障害の治療および予防のための腸管選択的隔離剤 | |
| US8647666B2 (en) | Administration of an adsorbent polymer for treatment of systemic inflammation | |
| Shu et al. | Copper-bearing metal-organic framework with mucus-penetrating function for the multi-effective clearance of mucosal colonized Helicobacter pylori | |
| Idrovo et al. | AICAR attenuates organ injury and inflammatory response after intestinal ischemia and reperfusion | |
| Wu et al. | Protective Effect of Tetrandrine on Sodium Taurocholate‐Induced Severe Acute Pancreatitis | |
| US20190142866A1 (en) | Porous carbon particles for use in the treatment or prevention of liver disease | |
| Das et al. | Impact of glutaraldehyde on in vivo colon‐specific release of resveratrol from biodegradable pectin‐based formulation | |
| Xu et al. | Significance of the gut tract in the therapeutic mechanisms of polydopamine for acute cerebral infarction: neuro-immune interaction through the gut-brain axis | |
| Aminu et al. | Nanogel drug delivery system loaded with Azadirachta indica A. Juss.(Neem) for potential treatment of wound infection: development and characterization | |
| Yang et al. | Ameliorative effect of melatonin against increased intestinal permeability in diabetic rats: possible involvement of MLCK-dependent MLC phosphorylation | |
| Ke et al. | Development of resveratrol with thiolated alginate as a supplement to prevent nonalcoholic fatty liver disease (NAFLD) | |
| Cheung et al. | Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12‐week trials in Chinese patients with osteoarthritis or rheumatoid arthritis | |
| Freschi et al. | Increase in body weight is lowered when mice received fecal microbiota transfer from donor mice treated with the AT1 receptor antagonist telmisartan | |
| Chen et al. | Exploration of the wound healing potential of thermoplastic polyurethane electrospun membrane incorporated with phenolic acids in Spenceria ramalana Trimen | |
| EP4132473A1 (fr) | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales | |
| IT201900008265A1 (it) | Integratore alimentare a rilascio colonico come coadiuvante nel trattamento dei disturbi del colon causati da sospetta o confermata alterazione del quadro infiammatorio e destabilizzazione del microbiota |